- Each submission will be considered by at least two peer reviewers.
- The abstract does not need to represent new or innovative strategies; getting good results with a known strategy is valuable for the situational nuances demonstrated as well as the robustness of the strategy. Of course, brand new strategies, i.e. innovations, are also welcome.
- Failed projects are just as useful as successes if proper analysis occurs; results of poorly planned studies are less useful than good studies with disappointing outcomes. The key is whether others will learn something from the study that will help them improve patient outcomes.
- Although not required, interventions that increased laboratory spending while they also demonstrate improved patient outcomes and lowered overall institutional spending are of special interest.
- During the review process, some additional questions might be directed to the submitters concerning methodology and data analysis.
See below for ICE Scoring Criteria.
Scoring (Maximum: 50 points)
1. Background and Problem Statement (8)
a. Is the problem background clear? (0-no, 1-partially, 2-yes)
b. Is the rationale for prioritizing the problem for resolution clear? (0-no, 1-yes)
c. Does the problem statement explicitly identify the goal, i.e. benefit to be improved or the harm to be reduced? (0-no, 1- partially, 2-yes)
d. Is the description of the intervention to be used clear and complete? (0-no, 1-partially, 2-mostly, 3-yes)
e. Is the method/protocol well described (0-no, 1-partially, 2-mostly, 3-yes)
f. Is the setting clearly and appropriately defined, e.g. emergency room, primary care office, etc.? (0-no, 1- partially, 2-yes)
g. Is the patient population clearly and completely described, e.g. gender, age, minority status, insurance status, etc.? (0-no, 1-partially, 2-yes)
h. Are the utilized measures well-defined? (0-no, 1-partially, 2-yes)
i. Are the measures appropriate for the intervention? (0-no, 1-partially, 2-yes)
j. Are the measures linked to patient outcomes? Using the following four descriptions as guidelines, choose a single score that best reflects the strength of the linkage.
i. Direct measure of patient outcome e.g. time to diagnosis, reduced transfusions or antibiotics without negatively impacting other outcomes
such as length of stay; fewer adverse events (range of 8-10 points)
ii. Strong linkage to direct patient outcome, e.g. time out of therapeutic range, patient satisfaction; reduced readmissions (4-7)
iii. Moderate linkage to direct patient outcome, e.g. reduced rate of recollects (1-3)
iv. Weak linkage to direct patient outcome, e.g. reduced hemolysis or short fill rate no data on patient impact such that patient benefit can only be
k. Is the data collection process adequate for the problem? (0-2)
3. Analysis/Results (12)
l. Is the source of the data specified? (0-no, 1-yes)
m. Is the time span in which data is collected described and sufficient? (0-no, 1-partially, 2-yes)
n. Is the total volume of data meaningful? (0-no, 1-partially, 2-yes)
o. Is there a good comparator (baseline or control) from which to assess improvement? (0-no, 1-partially, 2-yes)
p. Is the statistical treatment of the collected data appropriate? (0-no, 1-partially, 2-yes)
q. Is at least one unfavorable impact identified and measured? (0-no, 1-done, but weak, 2-yes, 3-more than one)
4. Discussion/Lessons learned (7)
r. Was there adequate consideration of other factors (limitations) that could influence the data (0-no, 1-partially, 2-mostly, 3-yes)
s. Were the conclusions described and their applicability to other similar institutions? (0-no, 1-partially, 2-mostly, 3-yes)
t. Was there discussion of what will/has changed in the institution as a result of the work (0-no, 1-yes)
© 2015 Clinical Laboratory Management Association. All Rights Reserved.